Mild dementia from Alzheimer’s disease
The purpose of the study is to compare the effect of the study drug to that of a placebo on cognition for people with mild dementia due to Alzheimer’s Disease (AD). The study will last up to 32 weeks with up to 5 clinic visits and weekly telephone contacts after the first visit. While in the study, your study-related investigational medication, lab work and procedures are provided at no charge. If you qualify and enroll, you may be compensated for your time and travel.
Male & Female
Why take part?
Participants will receive study-related doctor’s care, study medication at no cost. Compensation for study-related time and travel may be available.
Millions of people lack the treatment they need to manage their conditions. As one of the largest and most recognized clinical study organisations in the world, Synexus provides a friendly relaxed environment where you have the opportunity to help others and maybe also yourself.
Who is Synexus?
Synexus is a company dedicated to conducting clinical studies, and has been investigating the effectiveness of new study drugs and treatments for more than 20 years. We provide a friendly, relaxed environment in our own clinics where you have the chance to help shape the future of health for yourself and for others.
We are sure you probably have more questions about the study, and we would be happy to take the time to give you more details.
All Synexus studies are approved by an independent ethics committee.